XML 19 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Management’s Plans	6 Months Ended
Jun. 30, 2021
Liquidity and Managements Plans [Abstract]
LIQUIDITY AND MANAGEMENT’S PLANS	NOTE 2 - LIQUIDITY AND MANAGEMENT’S PLANS As of June 30, 2021, the Company had cash and cash equivalents of approximately $52,067,000 and a working capital of approximately $53,923,000. The Company has not generated revenues from commercial operations since inception and has incurred recurring operating losses. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue its product development. The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to June 30, 2021. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific staff and continues to prepare for anticipated manufacturing activities. If we encounter unforeseen delays or expenses, we have the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.

Liquidity and Management’s Plans

6 Months Ended

Jun. 30, 2021

Liquidity and Managements Plans [Abstract]

NOTE 2 - LIQUIDITY AND MANAGEMENT’S PLANS

As of June 30, 2021, the Company had cash and cash equivalents of approximately $52,067,000 and a working capital of approximately $53,923,000. The Company has not generated revenues from commercial operations since inception and has incurred recurring operating losses. The Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to pursue its product development.

The Company expects to further increase its research and development activities, which will increase the amount of cash utilized subsequent to June 30, 2021. Specifically, the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional and scientific staff and continues to prepare for anticipated manufacturing activities. If we encounter unforeseen delays or expenses, we have the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements.